Clinical trials
Lymphoma clinical trials
Cancer of the lymphatic system, part of the body’s immune defenses. We’re tracking 1,332 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05296304RecruitingPhase 1
Bexarotene plus radiation for mycosis fungoides skin lymphoma
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
Commack, New YorkAges 18 years+ - NCT05237986Recruiting
Study brain and thinking effects after CAR T therapy in youth
This study looks at how CAR T-cell treatment affects thinking, learning, and day-to-day brain function in children and young adults with certain blood cancers. You (and a caregiver) may complete online testing so researchers can track these changes over time and whether support is needed.
Los Angeles, CaliforniaAges 5 years+ - NCT05257018RecruitingPhase 2
Chemo plus medicine in the spine to prevent lymphoma brain relapse
This Phase 2 study tests whether adding intrathecal methotrexate (a cancer drug delivered into the spinal fluid) to standard chemo can lower the risk of diffuse large B-cell lymphoma (DLBCL) coming back in the brain or spinal fluid. It is for people with higher-than-usual risk of central nervous system (CNS) relapse.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05235633Enrolling by invitation
Daily activities after cancer treatment in children
This study looks at how children and teens manage everyday activities like dressing, eating, and moving around right after finishing treatment for leukemia or lymphoma. It aims to understand their needs and help improve recovery support.
MunichAges 4–18 - NCT05170399RecruitingPhase 4
Testing how cancer vaccines work in B-cell blood cancers
This study measures how well certain vaccines stimulate the immune system in people with B-cell blood cancers such as CLL and different types of lymphoma or Waldenström macroglobulinemia. It may help doctors better predict who will benefit most from vaccination and improve vaccine planning for these conditions.
Bethesda, MarylandAges 18–90 - NCT05156203RecruitingPhase 1
T-1301 capsule study for advanced solid tumors
This trial tests a new oral drug, T-1301, for people with advanced solid tumors (including lymphoma) that have stopped responding to standard treatments. The study aims to find a safe dose and see how the body responds.
Kaohsiung CityAges 20 years+ - NCT05147467RecruitingPhase 2
Trial of APG-2575 for returning or resistant CLL/SLL
This trial studies APG-2575 in people with CLL/SLL that has come back or is not responding to prior treatments. It may help shrink disease and improve control when standard options have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT05183854RecruitingPhase 2
Vaccine study for CLL patients to prevent pneumococcal infections
This trial tests a series of two pneumococcal vaccines (PCV20 and PPSV23) in people with CLL-related immune weakness. It aims to see how well the vaccines work and how safe they are for preventing serious lung infections.
Salt Lake City, UtahAges 18 years+ - NCT05091424RecruitingPhase 1
Mosunetuzumab with or without venetoclax for CLL
This Phase 1 study tests whether mosunetuzumab alone or with venetoclax is safe and effective for people with chronic lymphocytic leukemia (CLL) that came back or did not respond to prior treatment. It may help by controlling the CLL immune system response while also studying dosing and side effects.
Rochester, MinnesotaAges 18 years+ - NCT05135351Recruiting
Prebiotics to help your gut health after cancer cell treatment
This trial tests whether taking prebiotics (food for helpful gut bacteria) can improve gut microbiome diversity after your own cancer-cell treatment, like autologous stem cell transplant or CAR-T. It may help your gut ecosystem recover during and after therapy.
Omaha, NebraskaAges 19 years+ - NCT05093335RecruitingEarly Phase 1
PET scan test for CXCR4 in many relapsed cancers
This early study tests a new PET scan tracer (a radioactive imaging agent) that may light up a cell marker called CXCR4 in certain blood and solid tumor cancers. It may help doctors see where cancers are and how much CXCR4 they have, which could guide future treatments.
New York, New YorkAges 18 years+ - NCT05046444Recruiting
Testing tricky blood cancer diagnoses with advanced DNA sequencing
This study uses advanced DNA sequencing to figure out unclear or unusual blood (hematologic) conditions when standard tests are not enough. It may help your care team reach a more accurate diagnosis by better understanding what’s driving your illness.
MunichAges 18–99 - NCT05006482RecruitingPhase 3
Geriatric education and care support for older cancer survivors
This study tests whether a structured health education and “older adult care” approach—done with your oncology team—can improve support for people after cancer. It includes older cancer survivors and a chosen caregiver, using in-person or video visits for follow-up.
Tuscaloosa, AlabamaAges 18 years+ - NCT05018520RecruitingPhase 3
Two chemotherapy schedules for newly diagnosed low-risk DLBCL
This trial compares two different shortened treatment schedules of R-CHOP to see which one is safer and works better for people with low-risk diffuse large B-cell lymphoma (DLBCL). It aims to reduce risk from treatment while maintaining strong cancer control after an initial response.
Shanghai, Shanghai MunicipalityAges 14–75 - NCT04986293Recruiting
CPAP or BiPAP to reduce motion during radiation
This study tests whether using a breathing machine (CPAP or BiPAP) can help keep you still during radiation treatment. This may improve how accurately radiation is delivered for certain cancers treated with curative intent.
Groningen, Provincie GroningenAges 18 years+ - NCT04902443RecruitingPhase 1
Pomalidomide and nivolumab for virus-related cancers
This trial tests two drugs (pomalidomide and nivolumab) in people with cancers caused by viruses. The goal is to see if this combination can shrink or control tumors that haven't responded to standard therapies.
Bethesda, MarylandAges 18–99 - NCT04915248RecruitingPhase 2
Study of daratumumab, bortezomib, and dexamethasone for plasmablastic lymphoma
This trial tests how well a combination of daratumumab, bortezomib, and dexamethasone works in people with plasmablastic lymphoma that has returned or did not respond to prior treatment. It aims to shrink measurable tumors and improve outcomes, including for some people living with HIV.
Ancona, AnconaAges 18 years+ - NCT04914091Recruiting
Study comfort and medication use after CAR-T therapy
This study looks at quality of life and how medicines are used for people who are getting CAR-T cell therapy for DLBCL. It aims to better understand what helps patients feel and function during follow-up after treatment.
Pierre-BéniteAges 18 years+ - NCT04898790Recruiting
Testing ways to improve thinking after bone marrow transplant
This study looks at whether a physical activity program and related study measures can improve thinking and memory in older adults around the time of a stem cell transplant. If you qualify and participate, the team will compare outcomes between groups to see what approach works best.
Omaha, NebraskaAges 19 years+ - NCT04904146Recruiting
Testing blood or tumor markers in skin lymphoma patients
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
LundAges 18–100 - NCT04726241RecruitingPhase 1/Phase 2
Testing blood and bone marrow samples in young leukemia patients
This trial looks at blood and bone marrow samples from children and teens whose leukemia has come back or is hard to treat. The goal is to better understand the disease and guide future options for these patients.
Birmingham, AlabamaAges Up to 22 years - NCT04752826RecruitingPhase 1/Phase 2
A new drug combo for advanced cancers
This trial tests a new experimental drug, BI-1808, alone or with an approved cancer drug called pembrolizumab (Keytruda). It's for people with advanced cancers that have stopped responding to standard treatments.
Duarte, CaliforniaAges 18 years+ - NCT04728893RecruitingPhase 2
Nemtabrutinib for blood cancers after prior treatment
This Phase 2 trial tests nemtabrutinib (MK-1026), an oral medicine, in people with certain blood cancers that have come back or didn’t respond to earlier treatments. It aims to see how well the drug works and whether it is safe.
Springdale, ArkansasAges 18 years+ - NCT04627753RecruitingPhase 2
Lenalidomide plus rituximab to prevent brain lymphoma return
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
SeoulAges 19 years+
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lymphoma?
- Yes. Clin2 currently lists 1,332 recruiting lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.